ArticleFederal practitioner : for the health care professionals of the VA, DoD, and PHS2025
A Systemic Lupus Erythematosus Incidence Surveillance Report Among DoD Beneficiaries During the COVID-19 Pandemic.
Article in Federal practitioner : for the health care professionals of the VA, DoD, and PHS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Concerns have been raised regarding the potential for COVID-19 infection to precipitate the development of systemic lupus erythematosus (SLE). This surveillance analysis was conducted to determine the incidence of SLE among US Department of Defense (DoD) beneficiaries before and during the COVID-19 pandemic. Methods: Outpatient encounters, private sector care records, and laboratory data from January 1, 2018, through December 31, 2022, were analyzed. Data from 2017 were used to exclude previously diagnosed cases. Inpatient data also were excluded. Positive lupus cases were identified through a combination of laboratory results and relevant Results: A consistent decrease in SLE incidence was observed during the COVID-19 pandemic, with total cases declining from 2866 in 2018 to 1399 in 2022 among DoD health care beneficiaries. The mean annual decline of 16.0% and an overall reduction of 48.2% from 2018 to 2022 displayed consistent patterns across subgroups stratified by sex, age, and beneficiary type. Conclusions: The results of this study do not show an increase in SLE incidence among DoD beneficiaries during the COVID-19 pandemic. These findings suggest that the mitigation strategies implemented within the DoD to reduce COVID-19 transmission may have contributed to this trend. Further research is warranted to monitor SLE incidence over time, with attention to broader environmental changes and shifting patterns of common infections.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.